Nitrosamine Impurities: A Regulatory Perspective
In July 2018, the European medicines regulatory network became aware of the presence of nitrosamine impurities in an Active Pharmaceutical Ingredient (API). This was the first time that a nitrosamine impurity had been detected in a pharmaceutical drug. The unexpected delivery of these impurities resulted in voluntary product recalls on a mass scale and led …
Nitrosamine Impurities: A Regulatory Perspective Read More »